This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Windlas Sep 2026 quarter revenue up 18.7%, but EBITDA margin narrows
WINDLAS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 9.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 30, 2026: revenue was Rs 2,639.08 million, up 18.7% from Rs 2,223.98 million a year earlier; profit after tax was Rs 180.52 million, up 1.4% from Rs 178.00 million. EBITDA margin fell 1.7 points to 11.1%. Standalone half-year revenue was Rs 5,120.07 million, profit after tax Rs 357.05 million and operating cash flow Rs 534.79 million. The US subsidiary was dissolved, ending consolidated reporting.
Mildly negative for sentiment: sales rose, but profit was nearly flat and the operating margin narrowed, despite healthy operating cash flow.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹263.9 Cr | ₹222.4 Cr | +18.7% |
| Operating profit | ₹19.44 Cr | ₹19.94 Cr | −2.5% |
| Profit after tax | ₹18.05 Cr | ₹17.80 Cr | +1.4% |
| EBITDA margin | 11.1% | 12.8% | −1.7 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.